Nitric Oxide innovations LLC, (NOi) is positioned to advance patented nitric oxide (NO) science into new and innovative therapies for human disease across different markets.

 

The worldwide market involving NO-based therapies was $70 billion in 2018 and is projected to rise to $125 billion in 2023 and $195 billion in 2028 as new NO drugs are introduced into the market. Future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics. Focusing on proven nitric oxide patented technology, along with patented innovative delivery systems, Nitric Oxide innovations LLC will develop novel drug therapies ranging from topical drug deliveries to oral formulations for specific drug indications where safety and efficacy are already established including:

• Ischemia and no obstructive coronary artery disease (INOCA),

• Pulmonary hypertension

• Heart failure with preserved ejection fraction (HFpEF)

• Topical application for chronic wound/ulcer therapy

​

Each segment has multi-billion dollar market with unmet needs. The objective is to de-risk and show proof of concept for the opportunity for merger or acquisition by big Pharma.  Our FDA approved phase 2/3 clinical trial in African Americans with COVID leads our drug development program.  The success of Dr. Bryan’s patented NO science and product development in the nutraceutical and dietary supplement market provides the immediate name and brand recognition as leaders in the nitric oxide field. Sub-licensing for specific drug indications will allow leverage from existing companies to help defray the capital requirements for drug approval by Nitric Oxide Innovations, LLC.

​

Development and approval of new NO based drugs have been slow and largely unsuccessful due primarily to limitations in delivery of bio-active NO gas which has a half-life of less than one second. Technologies utilizing issued patents by Dr. Bryan has proven safety and efficacy in products that have been on the market for over 10 years in a number of human diseases ripe for drug development. Manufacturing, partnership, and drug candidates are already developed which will allow for rapid market penetration, especially our COVID drug.

​

Proven safety and efficacy of products utilizing Dr. Bryans patented NO technology, new and patented NO delivery systems for topical delivery, a growing awareness of NO combined with unmet medical needs that our NO technology can meet positions Nitric Oxide innovations at the forefront of NO based therapies across multiple market

segments.